Live webcast fireside chat on Wednesday, June 21st at 12:00 PM ETOCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM…
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting and General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or…
DOYLESTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused…
Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib,…
225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with pembrolizumab, in patients with advanced…
SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering…
BOSTON, June 14, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of…
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response…
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent…
Collaboration with Researchers at University of Oxford to Utilize State-of-the-Art Technology to Characterize Immune Synapse Formation Mediated by First-In-Category EVOLVE…